Healios K.K. announced on July 11th, 2023 that it decided to establish a subsidiary to promote the development of its eNK pipeline, with a focus on solid tumors, using NK cells derived from allogeneic iPSCs and whose specific functions have been enhanced with gene editing technology. The company determined the initial details of this subsidiary. Name of the subsidiary: eNK Therapeutic Inc. Location: Chiyoda-ku, Tokyo.

Representative director: Hikaru Saito, PhD. Business: Research, development, manufacturing and marketing of pharmaceutical products. Paid in capital ¥1. Date of establishment: August 14, 2023.